Page 1

TFF PHARMACEUTICALS FOR IMMEDIATE RELEASE EXHIBIT 99.1 TFF Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update Pivotal Trials to Begin in 2H - 2021 for Voriconazole Inhalation Powder for the Treatment of Invasive Pulmonary Aspergillosis ( IPA ) and Tacrolimus Inhalation Powder for Immunosuppression in Solid Organ Transplantation Patent Filed for Once - a - Day Dosing for Tacrolimus Inhalation Powder , Achieving Therapeutic Blood Levels with a Single Low Dose Science Day to be Held in June to Highlight Thin Film Freezing Platform Technology Conference Call and Live Webcast Scheduled Today , Thursday , May 13 , 2021 , at 4:30 pm EDT AUSTIN , TX -- May 13 , 2021 --TFF Pharmaceuticals , Inc. ( NASDAQ : TFFP ) , a clinical - stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing ( TFF ) technology platform , today reported financial results for the first quarter ended March 31 , 2021 , as well as provided a business update on recent corporate and clinical developments . The Company will discuss the clinical , corporate and financial highlights on a conference call and live webcast , scheduled today , Thursday , May 13 , 2021 , at 4:30 pm EDT . " We continue to make progress with our clinical development programs : Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder , " said Glenn Mattes , President and CEO of TFF Pharmaceuticals . " This progress , along with better - than - expected clinical data , will allow us to initiate clinical trials designed to achieve registration for both of these important programs by the end of 2021. " " The data we have seen from our Tacrolimus Inhalation Powder trial suggests that we can achieve efficacious immunosuppressive blood levels of tacrolimus with an inhaled , once - a - day , low - dose formulation , " said Mattes . " We believe that inhaled tacrolimus ' ability to reduce the fluctuations of bioavailability offers a compelling advantage over oral tacrolimus , as physicians often attribute the peaks and troughs of oral delivery with suboptimal efficacy and exacerbated side effects . ” " We have filed a US patent based on this once - a - day dosing development , which could have major implications for lung transplant patients , and potentially for heart , kidney and liver transplant patients as well , " continued Mattes . " Based on our recent research , we believe the peak yearly sales of tacrolimus in all four indications could exceed $ 1 billion dollars . " " This quarter , we've also made notable progress with a number of our strategic partners , " said Mattes . “ Our collaborations with UNION therapeutics on niclosamide and Augmenta Bioworks on monoclonal antibodies are progressing on plan , and our partner in the cannabis space , PLUS Products , is seeing positive initial manufacturing data and strong market interest .